RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Dermapharm Holding P/S 2024

Dermapharm Holding P/S

1.56

Dermapharm Holding Dividend yield

3.13 %

Ticker

DMP.DE

ISIN

DE000A2GS5D8

WKN

A2GS5D

As of May 6, 2024, Dermapharm Holding's P/S ratio stood at 1.56, a -30.67% change from the 2.25 P/S ratio recorded in the previous year.

The Dermapharm Holding P/S history

Dermapharm Holding Aktienanalyse

What does Dermapharm Holding do?

Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich. Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications. The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products. Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products. Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women. Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils. Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products. Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Dermapharm Holding's P/S Ratio

Dermapharm Holding's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Dermapharm Holding's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Dermapharm Holding's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Dermapharm Holding’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Dermapharm Holding Stock

What is the price-to-earnings ratio of Dermapharm Holding?

The price-earnings ratio of Dermapharm Holding is currently 1.56.

How has the price-earnings ratio of Dermapharm Holding changed compared to last year?

The price-to-earnings ratio of Dermapharm Holding has increased by -30.67% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Dermapharm Holding high compared to other companies?

Yes, the price-to-earnings ratio of Dermapharm Holding is high compared to other companies.

How does an increase in the price-earnings ratio of Dermapharm Holding affect the company?

An increase in the price-earnings ratio of Dermapharm Holding would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Dermapharm Holding affect the company?

A decrease in the price-earnings ratio of Dermapharm Holding would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Dermapharm Holding?

Some factors that influence the price-earnings ratio of Dermapharm Holding are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Dermapharm Holding pay?

Over the past 12 months, Dermapharm Holding paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 3.13 %. For the coming 12 months, Dermapharm Holding is expected to pay a dividend of 1.14 EUR.

What is the dividend yield of Dermapharm Holding?

The current dividend yield of Dermapharm Holding is 3.13 %.

When does Dermapharm Holding pay dividends?

Dermapharm Holding pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Dermapharm Holding?

Dermapharm Holding paid dividends every year for the past 0 years.

What is the dividend of Dermapharm Holding?

For the upcoming 12 months, dividends amounting to 1.14 EUR are expected. This corresponds to a dividend yield of 3.41 %.

In which sector is Dermapharm Holding located?

Dermapharm Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dermapharm Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dermapharm Holding from 7/2/2024 amounting to 0.88 EUR, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Dermapharm Holding pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Dermapharm Holding in the year 2023?

In the year 2023, Dermapharm Holding distributed 2.17 EUR as dividends.

In which currency does Dermapharm Holding pay out the dividend?

The dividends of Dermapharm Holding are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dermapharm Holding stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital

Andere Kennzahlen von Dermapharm Holding

Our stock analysis for Dermapharm Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dermapharm Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.